From d12dacec1aacb81f427893933844dc135a99ad3e Mon Sep 17 00:00:00 2001 From: stephany28w720 Date: Wed, 8 Oct 2025 13:39:56 +0200 Subject: [PATCH] --- Dianabol-Cycle%3A-FAQs-And-Harm-Reduction-Protocols.md | 7 +++++++ 1 file changed, 7 insertions(+) create mode 100644 Dianabol-Cycle%3A-FAQs-And-Harm-Reduction-Protocols.md diff --git a/Dianabol-Cycle%3A-FAQs-And-Harm-Reduction-Protocols.md b/Dianabol-Cycle%3A-FAQs-And-Harm-Reduction-Protocols.md new file mode 100644 index 0000000..0285205 --- /dev/null +++ b/Dianabol-Cycle%3A-FAQs-And-Harm-Reduction-Protocols.md @@ -0,0 +1,7 @@ +Dianabol Cycle: FAQs And Harm Reduction Protocols +
Clinical presentation / age of onset – MPS IIIa (Sanfilippo type A)
+
+FeatureWhat the literature says +Typical age when first signs appearThe article notes that symptoms "may be present early in life," but it does not provide a specific age range or average. In clinical practice, manifestations usually become apparent between 2–4 years of age (often earlier for more severe variants). +Early‑onset symptomsThe review lists the classic neuro‑cognitive phenotype—progressive intellectual decline and behavioral changes—but does not detail the earliest specific signs (e.g., speech delay, sleep disturbances). +Onset of motor/neurological deficitsNo age data is given \ No newline at end of file